Winter J N, Ritch P S, Rosen S T, Oken M M, Wolter J M, Wiernik P H, O'Connell M J
Northwestern University Medical School, Chicago, Illinois.
Cancer Invest. 1990;8(2):143-6. doi: 10.3109/07357909009017559.
Twenty patients with refractory multiple myeloma were treated with methylglyoxal-bis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.
二十名难治性多发性骨髓瘤患者接受了甲基乙二醛双（脒腙）（MGBG）治疗，MGBG是一种多胺合成抑制剂。在第1天和第8天给予MGBG 500mg/m²，然后每14天给药一次。根据耐受情况，在第22天将剂量增至600mg/m²。在14名可评估的患者中，无人达到ECOG客观缓解标准。主要毒性为血液学毒性及相关感染。MGBG在难治性多发性骨髓瘤治疗中显示出的活性不足，不值得进一步研究。
